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Suicidal behaviors (SBs), which range from suicidal ideation to suicide attempts and 
completed suicide, represent a fatal dimension of mental ill-health. The involvement of 
genetic risk factors in SB is supported by family, twin, and adoption studies. The aim 
of this paper is to review recent genetic association studies in SBs including (i) case–
control studies, (ii) family-based association studies, and (iii) genome-wide association 
studies (GWAS). Various studies on genetic associations have tended to suggest that 
a number of genes [e.g., tryptophan hydroxylase, serotonin receptors and transporters, 
or brain-derived neurotrophic factors (BDNFs)] are linked to SBs, but these findings 
are not consistently supported by the results obtained. Although the candidate–gene 
approach is useful, it is hampered by the present state of knowledge concerning the 
pathophysiology of diseases. Interpretations of GWAS results are mostly hindered by 
a lack of annotation describing the functions of most variation throughout the genome. 
Association studies have addressed a wide range of single-nucleotide polymorphisms 
in numerous genes. We have included 104 such studies, of which 10 are family-based 
association studies and 11 are GWAS. Numerous meta-analyses of case–control studies 
have shown significant associations of SB with variants in the serotonin transporter gene 
(5-HTT or SLC6A4) and the tryptophan hydroxylase 1 gene (TPH1), but others report 
contradictory results. The gene encoding BDNF and its receptor (NTRK2) are also prom-
ising candidates. Only two of the GWAS showed any significant associations. Several 
pathways are mentioned in an attempt to understand the lack of reproducibility and the 
disappointing results. Consequently, we review and discuss here the following aspects: 
(i) sample characteristics and confounding factors; (ii) statistical limits; (iii) gene–gene 
interactions; (iv) gene, environment, and by time interactions; and (v) technological and 
theoretical limits.
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FiGuRe 1 | Flow chart illustrating the selection of suicide behaviors 
association genetic studies.
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iNTRODuCTiON
There are roughly one million suicides worldwide annually, 
corresponding to an estimated yearly mortality rate of 14.5 
deaths per 100,000 population (1). In Europe, suicide represents 
the second leading cause of mortality in the 14–24 age groups 
(2). Suicide constitutes a multifactorial public health issue that 
involves numerous biological, psychological, cultural, social, 
and family determinants (3, 4). Support for the implication 
of genetic risk factors in suicidal behavior (SB) is provided 
by studies of families (5), twins (6–8), and adoption cases. 
Studies of adoption have also shown that there is a higher risk 
of suicide for the individuals who are biologically related to 
suicidal probands, but not for non-biologically related members 
of adoptive families (9–11). The recent findings of a large body 
of studies suggest significant heritability (h2) of completed 
suicide, with an aggregate estimate of h2 = 45% (3, 12, 13). The 
heritability appears to depend in part on psychiatric disorders 
such as mood disorders and substance abuse, with ~90% of 
suicide attempters having a psychiatric disorder (14–16), and, 
importantly, to also be partly independent of them (5, 10). 
This independent factor has been hypothesized to influence 
impulsive aggression, with individuals who have both of these 
personality traits and a major mental disorder having the great-
est risk of SB (17, 18).
Environmental factors such as early adverse experiences, 
including sexual and physical abuse during childhood, also 
strongly impact the risk of SB (19, 20). Some of them are liable 
to produce direct effects, while others will be controlled through 
risk for psychiatric disorders, which increases the risk for SB 
(21). Understanding of the precise genetic system that causes 
vulnerability to suicidal tendencies is largely incomplete, and 
efforts to identify the precise molecular mechanisms that are 
involved have been hampered by the large heterogeneity that is 
found within groups of SB. The generally accepted and regarded 
model for the genetic determinism of the SB is a polygenic 
model that involves a large number of genetic variants, each 
of which contributes a small modulation of risk. Therefore, 
association studies that are capable of detecting small effects 
are likely to be more useful. The majority of studies on genetic 
SB are based on the hypothesis of “common-disease common-
variant.” It is estimated that in the genome, there are more 
than 10 million common variations (≥5% frequency), most 
of which are variations of a single base, i.e., single-nucleotide 
polymorphisms (SNPs).
Two methods are used in particular: genome-wide asso-
ciation studies (GWAS) and gene–candidate association studies. 
The methodology that has been predominant in the published 
genetic studies of SB is that of functional candidate–gene studies 
(with physiopathological hypotheses) (22–26). This review of the 
literature aims to summarize the results of SB association studies 
which are currently available. We have also listed the studies of 
adolescent populations because, to the best of our knowledge, 
there are no specific reviews of this population. In the second 
part, we will discuss the limitations of the association studies and 
new perspectives on the understanding of SB and a broader view 
of complex diseases.
MeTHODS
Literature Search
An electronic search of the literature was performed to identify 
association studies that investigated the link between genetic vari-
ants and SB. A systematic search was conducted using PubMed, 
SCOPUS, and ISI Web of Science. The key words used to conduct 
the search were: “suicid*” in association with “gene*,” “polymor-
phism,” “haplotype,” “association,” “linkage,” or “genome wide.” 
We also examined the reference sections from the selected papers 
to identify any additional relevant studies.
Study Selection
Papers were included in the systematic review if they fulfilled the 
following criteria: (i) they were published in an English-language 
peer-reviewed journal from January 2004 to September 2015; 
(ii) they analyzed the association between any genetic SNP and 
SB, suicide attempt, or suicide completion; and (iii) they involved 
adolescent and/or adult subjects. An exclusion of identified irrel-
evant studies was performed in several steps: (i) duplicates were 
automatically identified; (ii) studies that referred to non-human 
subjects were automatically identified; (iii) studies that pertained 
to cancer research were automatically identified (using keywords 
such as tumour*, oncolog*, metastas*, or cancer); and (iv) studies 
of enrolled patients with self-harm without intent to die were 
identified. The texts of the studies that passed the initial screening 
were reviewed in extenso and potentially excluded, based on the 
same criteria. We clustered the retained papers into “candidate–
gene association studies” and “genome-wide association studies.” 
With respect to the PRISMA statement (27), the literature search 
strategy is summarized in the flow chart presented in Figure 1.
ReSuLTS
Candidate–Gene Association Study
Serotonergic System
The serotonergic pathway has been implicated for several 
decades  as having a major role in the pathophysiology of SB 
TABLe 1 | Details of studies included in the review for serotonergic genes.
Reference variants Suicide outcome/
diagnosis
Sample investigated Findings Populations
Tryptophan hydroxylase (TPH1)
Zalsman et al. (34) A218C SA-adolescent 
inpatients
88 SA+, and 49 family trios No association Jewish
Courtet et al. (35) A218C SA-psychiatric 
patients
103 SA+  
(20 repeaters vs. 56)
No association Caucasian 
(France)
Ohtani et al. (36) A779C, A218C Completed suicide 134 vs. 325 healthy controls No association Japanese
Stefulj et al. (37) C7065T, A218C Violent suicide  
victims
60 vs. 284 healthy controls No association Caucasian 
(Croatia)
Liu et al. (38) A218C, 
A779C + 3SNP
SA-psychiatric 
patients
297 SA+, 329 SA−,  
184 healthy controls
Haplotype TCAAA of -7180/-7065/-
6526/218/779 * SA, OR = 1.62 (1.17–2.24) 
p = 0.00243
Chinese
Stefulj et al. (39) A218C Violent suicide  
victims
247 vs. 320 controls CC was increased in older (>65 years) 
victims (p = 0.0126) Caucasian (Croatia)
Viana et al. (40) A218C SB-psychiatric 
patients
248 SA+ vs. 63 healthy  
controls
No association Brazilian
Galfalvy et al. (41) A218C, A6526G SA-depressive  
disorders
160 SA+ vs. 183 SA− AA of both * SA (p < 0.01) Caucasian, 
African-American
Brezo et al. (19) 143 SNPs  
(11 genes)
SA-prospective 
cohort
1121 (follow-up) 117 SA+ rs10488683 * SA, OR = 1.98  
(1.21–3.24) p < 0.001
Caucasian 
(Quebec)
Buttenschøn  
et al. (42)
5 SNP Completed suicide 572 vs. 1049 controls No association Caucasian 
(Denmark)
Bellivier et al. (43) A218C SB-meta-analysis 9 studies: 861cases,  
1485 controls
A allele * SB, OR = 1.62 (1.26–2.07) Caucasian 
(France)
Li and He (44) A779C, A218C, 
A6526G
SB-meta-analysis 34 studies: 3922 cases,  
6700 controls
A allelle * SB, OR = 1.14 (1.1–3) p = 0.0496 Caucasian 
(Europe)
Saetre et al. (45) A218C,  
A779C + 3 SNP
SB-meta-analysis 12 studies: 1272 cases,  
1727 controls
No association Caucasian 
(Europe)
Clayden et al. (46) A218C SB-meta-analysis 14 studies: 3479 cases,  
5945 controls
A allele * SB, OR = 1.22 (1.05–1.41) 
p = 0.007
Various
Tryptophan hydroxylase (TPH2)
Zill et al. (47) rs1386494,  
G19918A
CS-alcohol use  
disorders
263 vs. 263 healthy  
controls
G allele * suicide, p = 0.0038; 
p corr. = 0.038
Caucasian 
(Germany)
Zhou et al. (48) G703T,  
A473T + 13 SNPs
SA-depressive 
disorders
377 SA+ vs.1652 controls yin haplotype 212121 * SB in both 
populations
Finnish and 
African-American
Ke et al. (49) rs7305115 SA-MDD 102 SA+ vs. 123 SA− A allelle * SA p = 0.0067 Chinese
Lopez de  
Lara et al. (50)
14 SNPs CS-MDD 114 CS vs. 259 SA− rs4448731, rs6582071, rs4641527, 
rs1386497 * suicide (p < 0.005)
Canadian
Must et al. (51) G19918A Completed suicide 288 vs. 327 healthy controls No association Estonian
Mouri et al. (52) A473T, G19918A, 
G703T
Completed suicide 234 vs. 260 controls No association Japanese
Fudalej et al. (53) rs1386483 Completed suicide 143 vs. 163 controls TT * suicide (p = 0.02), repeated SA 
(p < 0.0001)
Caucasian 
(Poland)
Zhang et al. (54) r7305115 SA-MDD 215 SA+ vs. 215 SA− AA * SB, OR = 0.33 (0.22–0.99) p < 0.001 Chinese
Zupanc et al. (55) A473T CS-alcohol use  
disorders
388 vs. 227 controls No association Caucasian 
(Slovenia)
Stefulj et al. (56) G703T Violent suicide  
victims
291 vs. 280 controls No association Caucasian 
(Croatia)
Musil et al. (57) rs1386494 TESI-depressive  
disorder
22 TESI, 117 No TESI SA+, 
130 SA−
CT + TT * TESI (p = 0.0225) Caucasian 
(Germany)
Buttenschøn  
et al. (42)
G19918A +  
4 SNPs
Completed suicide 572 vs. 1049 controls No association Caucasian 
(Denmark)
González-Castro 
et al. (58)
G703T, A473T, 
G19918A
SB-meta-analysis 37 studies: 4196 cases,  
5990 controls
No association Various
CS, completed suicide; MDD, major depressive disorder; SA, suicide attempt; SA+, suicide attempters; SA−, patient without a history of suicide attempt; SB, suicidal behavior;  
SI, suicide ideations; SNP, single-nucleotide polymorphism; TESI, treatment emergent suicidal ideations.
*Associated with.
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(28–30). A number of reviews of the literature, including those 
of Anguelova et al. (31), Brezo et al. (32), and Antypa et al. (33), 
have studied the association of SB with common serotonergic 
gene polymorphisms. These studies mainly pertain to the 
following: (i) tryptophan hydroxylase (TPH), (ii) serotonin 
transporter (5-HT), and (iii) serotonin receptors (from 5-HT1 
to 5-HT7 with several subtypes and isoforms 5-HT1A, 5-HT2A, 
and others). We have included 40 studies and 8 meta-analyses. 
Tables 1 and 2 summarize the studies we selected on the main 
serotonergic genes.
TABLe 2 | Details of studies included in the review for serotonergic genes.
Reference variants Suicide outcome/ 
diagnosis
Sample investigated Findings Populations
Serotonin receptor 1A (5HTR1A)
Wasserman et al. (59) C1019G  
(HTR1A)
SA-psychiatric patients 272 nuclear family trios G-allele*SA in a sub-sample selected 
for high level of previous traumatic life 
events t (p = 0.063)
Ukraine
Videtic et al. (60) C1019G Completed suicide 323 vs. 190 controls No association Caucasian 
(Slovenia)
Wrzosek et al. (61) C1019G SA-alcohol use disorders 38 SA+, 110 SA− No association Caucasian 
(Poland)
Samadi Rad et al. (62) C1019G Completed suicide 191 vs. 218 healthy controls G allele * suicide (p = 0.001) Iranian
Höfer et al. (63) C1019G +  
4 SNPs
SA-resistant depression 160 SA−, 190 SA+ No association Caucasian, 
European
Angles et al. (64) C1019G SB-meta-analysis 4 studies: 957 cases,  
957 controls
No association Caucasian 
and Asian
Serotonin receptor 1B (5HTR1B)
Murphy et al. (65) G861G +  
27 SNP
SA-psychiatric patients 76 SA+, 83 SA− CG * SA (p = 0.047) Caucasian 
(Ireland)
Zouk et al. (66) T261G, A161T, 
C129T, G861C
Completed suicide 338 vs. 358 controls T allele of A-161T * Suicide (p = 0.05) Caucasian 
(Quebec)
Kia-Keating et al. (67) G861C SB-meta-analysis 7 studies: 789 cases,  
1247 controls
No association Caucasian 
and Asian
Serotonin receptor 2A (5HTR2A)
Zalsman et al. (68) T102C SA-adolescent inpatients 30 nuclear family trios No association Jewish 
Ashkenazi
Giegling et al. (69) A1438G +  
24 SNP
Suicide attempters 203 SA+ vs. 363 healthy  
controls
Haplotype A–C–T (rs643627- 
rs594242-rs6311) * SB (p = 0.037)
Caucasian 
(Germany)
Fanous et al. (70) T102C +  
11 SNPs
SI-schizophrenia 722 SI− vs. 127 SI+ No association Caucasian 
(Ireland)
Yoon and Kim (71) A1438G SA-MDD 181 SA+, 143 SA−, 176 controls No association Korean
Wrzosek et al. (61) T102C SA-alcohol use disorders 38 SA+, 110 SA− CC * SA in females (p = 0.02) Caucasian 
(Poland)
Zalsman et al. (72) T102C SA-adolescent inpatients 30 SA+ vs. 95 controls TT * lower impulsivity (p = 0.03) Jewish
Saiz et al. (73) A1438G +  
7 SNPs
SA-psychiatric patients 227 SA+, 686 SA−, 420 controls GG * Impulsive SA, OR = 1.88 
(1.26–2.83) p corr. = 0.016
Caucasian 
(Spain)
Ben-Efraim et al. (74) 51 SNPs SA-psychiatric patients 660 nuclear family trios rs17289304, rs6310, rs6305 * SA Ukraine
Höfer et al. (63) A1438G +  
4 SNPs
SA-resistant depression 190 SA+, 160 SA− No association Caucasian, 
European
Li et al. (75) T102C SB-meta-analysis 25 studies: 1954 cases,  
2860 controls
No association European and 
Asian
Li et al. (75) A1438G SA-meta-analysis 7 studies No association Asian
Serotonin transporter (SLC6A4)
De Luca et al. (76) 5-HTTLPR, 
VNTR
SA-bipolar disorders 86 SA+ vs. 250 SA− No association Canadian
Segal et al. (77) 5-HTTLPR SA-MDD 84 SA+ vs. 152 healthy controls No association Brazilian
Wasserman et al. (78) 5-HTTLPR SA-psychiatric patients 85 SA+ SS * lethality (p < 0.0026) Caucasian, 
Ukrainian
Segal et al. (79) 5-HTTLPR SA-MDD 94 SA+ vs. 94 healthy controls No association Brazilian
Coventry et al. (80) 5-HTTLPR SI-community sample 3242 subjects No association European 
(Australia)
Neves et al. (81) 5-HTTLPR Bipolar disorders 86 SA+, 112 SA−, 103 controls S allele * violent SA (p < 0.0001) Brazilian
Saiz et al. (73) 5-HTTLPR +  
7 SNPs
SA-bipolar disorders 227 SA + , 668 SA−, 420 controls S allele * lethality, OR = 2.16  
(1.15–4.08) p = 0.016
Caucasian 
(Spain)
Hung et al. (82) 5-HTTLPR SA-schizophrenia 60 SA+, 108 SA−,  
302 healthy controls
L allele * SA (p = 0.035) Chinese
Buttenschøn et al. (42) 5-HTTLPR +  
4 SNPs
Completed suicide 572 vs. 1049 controls No association Caucasian 
(Denmark)
Lin and Tsai (83) 5-HTTLPR SA, SC-meta-analysis 18 studies: 1521 SA+ or CS,  
2429 controls
No association Various
Li and He (84) 5-HTTLPR SA, SC-meta-analysis 39 studies: 3096 cases,  
5936 controls
S allele* SA, OR = 0.88 (0.8–0.97) 
p = 0.0068
European, 
Asian
Clayden et al. (46) 5-HTTLPR SB-meta-analysis 25 studies: 5363 cases,  
9085 controls
S allele * SB, OR = 1.13 (1.05–1.21) 
p = 0.001, I2 = 2.5%
Various
CS, completed suicide; MDD, major depressive disorder; SA, suicide attempt; SA+, suicide attempters; SA−, patient without a history of suicide attempt; SB, suicidal behavior; 
SI, suicide ideations; SNP, single-nucleotide polymorphism; TESI, treatment emergent suicidal ideations.
*Associated with.
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Tryptophan Hydroxylase
Tryptophan hydroxylase, the rate-limiting enzyme in the biosyn-
thesis of serotonin (5-HT), is a pre-eminent candidate for genetic 
studies of association in numerous psychiatric disorders, includ-
ing SB (85). Two genes that code TPH have been identified (TPH1 
and TPH2); TPH2 encodes for the main 5-HT-synthesizing 
enzyme in neurons, while TPH1 is predominantly expressed in 
peripheral tissue (5, 86).
TPH1. Three polymorphisms have been examined extensively: 
A218C, located in a potential GATA transcription factor-bind-
ing site, A779C located on intron 7, and A6526G located on the 
promoter region. The A allele A218C has been identified to be 
more frequent in suicide attempters compared to non-attempters 
(41). Galfalvy et al. (41) showed that the AA genotype on intron 
7 and the AA genotype on the promoter were both predictive of 
attempted suicides during the year-long observation period and 
were also associated with previous attempts of elevated lethality. 
This is a prospective study. The methodology used is relatively 
rare. The study by Courtet et al. (35) also uses a prospective design 
(1-year follow-up), but they find no association. On a clinical 
level, it is interesting to note that in the Galfalvy et al. (41) study, 
intron 7 genotype AA was associated with both fewer reasons for 
living and greater impulsivity. Regarding the C allele (A218C), 
only the study by Stefulj et al. (39) shows an association with SB 
just in people aged over 65 years. However, the association is rela-
tively weak, the number of subjects aged over 65 years is limited 
(n = 74), and the medical records of those who died could not all 
be obtained.
One study reported an association between haplotype TCAA 
of the -7180/-7065/-6526/218/779 SNPs and SB and psychiatric 
disorders (p  =  0.00243; OR  =  1.62; 95% CI 1.17–2.24 and 
p = 0.018; OR = 1.41; 95% CI 1.05–1.91), in the Asian population 
(38).
The Brezo et al. study (19) is unique in its design because it 
is a study in a cohort of 1255 members followed longitudinally 
over 22  years. The subjects were seen at different ages (child-
hood, mid-adolescence, early adulthood, and mid-adulthood). 
The DNA was collected at age 27.3 years, on average. The authors 
took into account environmental factors (family adversity, 
childhood sexual abuse, and childhood physical abuse) and 
numerous covariates such as DSM diagnoses, substance abuse, 
or history of psychopathology. The authors performed separate 
analyses in the samples of abused subjects and in the total 
sample. In the univariate analyses, several significant associa-
tions were identified in the total sample (TPH1-rs10488683 and 
HTR2A-rs1885884), and other associations in the sample of vic-
tims of sexual abuse (HTR2A-rs1885884, rs7997012, rs6561333 
and HTR5A-rs1440449). No gene–gene interaction was found. 
In the multivariate analyses, only one SNP (TPH1-rs10488683) 
made a statistically significant contribution independently of 
gender (OR =  1.2), parental suicide attempts (OR =  2.8), and 
axis I diagnoses (OR = 2.3). In summary, this study confirms that 
TPH1 gene variant (rs10488683) is specific to suicide attempts, 
with its G allele exerting a direct effect that is independent of 
gender and psychopathology and unmediated by childhood 
disruptiveness.
We found four meta-analyses that showed significant associa-
tions (43, 44, 46). Bellivier et al. (43) included 9 studies among 
the 15 identified and reported a significant association of the 
AA218C SNP allele with the risk of suicide in Caucasian popula-
tions. The odds ratios associated with the AA genotype and the 
AC genotype clearly suggest that the A allele increases the risk 
of SB in a dose-dependent manner, even after removing the two 
studies that had a significant heterogeneity.
The meta-analysis performed by Li and He (44) was concerned 
with three polymorphisms (A779C, A218C, and A6526G) and not 
just A218C. In addition, they included both European and Asian 
samples and analyzed them both combined and separately. This 
meta-analysis using multiple methods confirms a strong overall 
association between SB and the A779C/A218C polymorphisms 
in both populations. To obtain as much literature coverage as 
possible, they put equal emphasis on the positive and negative 
literature to avoid potential publication bias and maximize statis-
tical power and robustness.
Saetre et  al. (45) conducted a study with 837 Scandinavian 
schizophrenia patients and 1473 controls. They showed that 
three of the five SNPs tested, including A218C and A779C poly-
morphisms, were associated with schizophrenia susceptibility 
(p = 0.019), but they show no difference in allele frequencies of 
these loci between affected individuals having attempted suicide 
at least once and patients with no history of suicide attempts 
(p =  0.84). In the second part of their article, they conducted 
a meta-analysis of A218C/A779C and SB among individuals 
affected with a psychiatric disorder. They failed to find any effect 
of the TPH1 A779C/A218C SNPs on SB (0.96; 95% CI: 0.80–1.16). 
This result contradicts the hypothesis that TPH1 polymorphisms 
affect SB independently of mental health status. This is why the 
authors selected only those studies which had compared allele 
frequencies in suicidal and non-suicidal patients diagnosed with 
a psychiatric disorder. Although their study did not take care 
to distinguish between Asian and Caucasian populations, their 
results force a more rigorous interpretation of the previously 
reported association between TPH1 and SB. Thus, one may 
assume that TPH1 A218C/A779C polymorphisms are associated 
with increased susceptibility to psychiatric disorders in general, 
which in turn are characterized by an increased incidence of 
suicide.
TPH2. The human TPH2 gene, situated on chromosome 12q15, 
consists of 11 exons and covers a region of roughly 93.5 kb. In 
2004, Zill’s team was the first to find significant single SNP 
(rs1386494) and haplotype associations with suicide completion 
in a German sample (47). In this study, in which TPH2 was linked 
to SB, 10 single SNPs were used, to define a 28-kb region of the 
TPH2 gene throughout which LD is elevated, thereby showing 
that a haplotype block exists anywhere that a responsible func-
tional locus might be found.
We found nine studies that had significant associations in 
genotypic and/or haplotypic distributions of TPH2 variants 
between subjects who had SBs and controls (47–50, 53, 54, 57, 87).
For example, the study by Lopez de Lara et al. (50) included 
subjects who died by suicide during a major depressive disorder 
(MDD) and controls suffering from MDD. Moreover, all the 
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subjects were well characterized (Axis I and Axis II, psychologi-
cal autopsy procedure), and bipolar patients were excluded. Four 
SNPs were identified to be significantly associated with depressed 
suicide cases and remain significant after statistical adjust-
ments; two SNPs in the TPH2 5′ upstream region (rs4448731 
and rs6582071) and two SNPs in introns 1 (rs4641527) and 8 
(rs1386497). Alleles T, G, G, and C of SNPs rs4448731, rs6582071, 
rs4641527, and rs1386497, respectively, were overrepresented in 
depressed suicide completers. In the second part, the authors 
conducted a series of logistic regressions to determine a possible 
interaction between genetic variants and other risk factors, and 
more specifically whether impulsive–aggressive behaviors (IBAs) 
may explain the relationship between TPH2 genetic variants and 
suicide completion. Their results do not confirm this hypothesis.
The variant (rs1386494) was previously identified by Zill 
et al. (47) but at the same time, the recent study by Buttenschøn 
et  al. (42), which examined over 500 subjects who died by 
suicide, found no association for TPH2 rs1386494. However, it 
is important to emphasize the methodology used in this study. 
The DNA of the cases was obtained from muscle tissue during 
the autopsy of subjects who died by violent death but with no 
certainty of suicide. Half of the controls are students for whom 
there is no clinical information apart from their age and ethnicity. 
The authors investigated five markers located within four genes 
(SLC6A4, MAOA, TPH1, and TPH2) involved in the serotoner-
gic system for association with suicide, but they found no robust 
association.
Zhou et  al. (48) showed that in both the tested populations 
(Finns and African-American), the yin haplotype 212121 was 
present more frequently in subjects who had attempted suicide. 
The “risk” haplotype found by Zhou et al. (48) is similar to hap-
lotype 1 of Zill et al. (47), and it was significantly more common 
among borderline patients (54). Haplotype linkage of TPH2 to 
SB, major depression, borderline disorder, and cerebrospinal 
fluid 5-hydroxyindoleacetic acid (a possible mediating pheno-
type) provides preliminary evidence that there is a functional 
locus that is potentially within a haplotype block of at least 52 kb 
in size. In two samples of Chinese depressed patients, Zhang 
et al. (54) and Ke et al. (49) showed that the TPH2 rs7305115 AA 
was still a significant protective predictor of SB (OR = 0.33 and 
OR = 0.35). The findings suggest that the carriers of the A → G 
mutation of the TPH2 rs7305115 SNP might run a greater risk 
of attempted suicide than the carriers of the AA homozygous 
genotype in MDD patients. More particularly, the results sug-
gest that the association between the SNP of the TPH2 gene and 
tendency to SB in major depression might be distinct from the 
heritability of mood disorders. Be that as it may, the absence in 
both studies of potentially functional SNPs indicates a pressing 
need for investigation of the polymorphisms present in both the 
TPH2 regulatory and adjacent regions.
Factors that contribute to treatment-emergent suicidal idea-
tion (TESI) using antidepressants have been the focus of recent 
research strategies. Musil et  al. (57) showed that the TPH2 
rs1386494 C/T polymorphism continued to display significant 
association with TESI in comparison with non-TESI (p = 0.0018; 
p =  0.0173 after 100,000 permutations). The TPH2 rs1386494 
C/T polymorphism had significant predictive power in logistic 
regression analysis (p = 0.0041), displaying an odds ratio of 5.64 
(95% CI 1.77–19.58). The haplotype block, which was found in 
this sample, accords well with the findings of studies conducted 
by Zill et al. (47) and by Zhou et al. (48). Polymorphisms in the 
TPH2 gene were studied in previous pharmacogenetic trials on 
TESI, yet none of these studies found any relevant association 
(88–91). However, the TPH2 rs1386494 C/T polymorphism was 
not included in the illumina chip of the STAR*D samples (90, 91) 
or the recent GWAS (89) (Detailed in the Section “Genome-Wide 
Association Study”).
Serotonin Receptor
5-HTR1A. The 5-HT1A receptor gene (HTR1A) is situated on 
chromosome 5 (5q11.2-13), and recent studies have found that a 
common C1019G polymorphism located in its promoter region 
probably plays a role in depression and SB. Since the first study 
by Lemonde et al. (92), which reported an association of SB with 
the rs6295 or C1019G variant, with attempters having a fourfold 
increased probability of being carriers of the GG genotype, few 
other teams have found significant associations. The Iranian study 
by Samadi Rad et al. (62) reported a greater frequency of the G 
allele in suicide victims compared with control groups. It is worth 
noting that this team found a higher number of more stressful life 
events (SLEs) for the subgroup of suicide victims with the GG 
genotype of C1019G polymorphism. In the same vein, the results 
obtained by Wasserman et al. (59) indicate a possible role of the 
G-allele in suicide attempters exposed to high levels of traumatic 
and/or SLEs. Although interactions with SLEs could be further 
investigated, the majority of studies reported negative results 
(59–61, 64, 93).
5-HTR1B. The HTR1B gene is an intronless gene that is located 
on chromosome 6. The study by Zouk et al. (66) found evidence 
suggesting a possible role of the promoter variant A161T in sui-
cide. An association was also observed between variation on this 
locus and levels of IAB. This study, like others, highlighted a pos-
sible intermediate phenotype, here IAB levels. IABs may indeed 
be a mediator, direct or indirect, of the association between 
genetic factors and suicide. This hypothesis is linked first to clini-
cal observations (impulsivity being a well-identified risk factor) 
and second to alterations of the serotonergic system (4, 11).
More recently, only the study by Murphy et  al. (65) found 
a significant association between rs6296 and suicide attempts 
(promoter CpG island of 5-5-HTR1B; p = 0.047).
5-HTR2A. The 5-HT2A receptor gene (HTR2A), located on 
chromosome 13 (13q14–q21), has been implicated in SB. The 
polymorphisms, which have received the most extensive investi-
gation, are the A1438G (rs6311) and T102C (rs6313). The genetic 
analyses carried out by Wrzosek et al. (61) found a prevalence of 
the more common CC genotype in the HTR2A T102C polymor-
phism in alcoholic subjects who had attempted suicide compared 
with those who had not made any suicide attempt.
In contrast, no association of T102C with SB was reported 
in a number of related case–control association studies (70, 71, 
95) and one meta-analysis (75). The meta-analysis by Li et al. 
(75) included a large number of studies, with comprehensive 
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analyses but also analyses in subgroups based on numerous vari-
ables such as ethnicity or gender. Although this meta-analysis 
adopted the random effect model (more conservative than the 
fixed effects model), significant confusion may arise from the 
fact that the authors studied two disorders, namely schizophre-
nia and SB. Moreover, the notion of SB is broad, ranging from 
suicidal ideation to completed suicide. The authors did, how-
ever, detect a significant association between A1438G and SB. 
Similarly, the study by Saiz et al. (73) showed that the HTR2A 
A1438A genotype frequencies trended toward being different 
in impulsive and planned suicide attempts. Genotype A/A was 
more frequently observed in planned attempts (31.5 vs. 17.9%), 
whereas the genotype G/G was more common in impulsive 
attempts (32.9 vs. 15.1%).
Höfer et al. (63) report no association (p < 0.05) between any 
SNP and either risk of suicide or a personal history of attempted 
suicides. Although interactions between 5HTR2A rs6313 
and 5HTR1A rs6295 in risk of suicide and between 5HTR2A 
rs643627 and 5HTR1A rs6295 in a personal history of attempted 
suicides have been identified (respectively, p = 0.027 and 0.036), 
the results did not persist after applying correction procedures for 
multiple testing. The authors conclude that their study fails to find 
any association of either 5HTR1A or 5HTR2A polymorphisms 
with a subject’s current risk of suicide or his/her past history of 
attempted suicide.
Family-based association studies constitute an alterna-
tive strategy for studying the variants as against case–control 
association studies. This approach also has the advantage of 
reducing the false positive and false negative results in cases of 
population stratification. Use is generally made of the haplotype 
relative risk (HRR) method (96). The alleles transmitted to the 
patient from the parents are compared with the alleles that were 
not transmitted. The non-transmitted parental alleles serve as 
controls. In addition to the HRR analyses, the Transmission 
Disequilibrium Test (TDT) (97) is used to analyze transmitted 
vs. non-transmitted alleles from heterozygote parents as another 
indicator of LD. Working with a cohort of 660 nuclear family 
trios (suicide attempters and both their parents), Ben-Efraim 
et  al. (74) confirms the association between genetic variation 
(rs6310 and rs6305) in the serotonin 2A receptor (HTR2A) gene 
and suicide attempt. A large part of this work was devoted to the 
study of gene–environment (G × E) interaction and included the 
study of parent-of-origin (POE). This study is of special interest 
because G ×  E interactions with SLEs are of importance in a 
stress–diathesis model of the suicidal process. As regards G × E 
interactions, the authors report a G × E between the exon 1 SNP 
rs6313 and exposure to cumulative types of SLEs. This G × E was 
independent of lifetime physical or sexual assault exposures. The 
heterozygote risk and TT-homozygote protective effects observed 
by this team in G × E agree with certain previous genetic findings 
on SA. In addition, their exploratory analysis revealed a signifi-
cant POE in this G × E in female subjects, which followed a polar 
overdominant inheritance pattern. POE in the presence of G × E 
suggests the importance of non-Mendelian inheritance patterns 
of HTR2A in the association with SA observed by Ben-Efraim 
et al. and may perhaps explain some of the inconsistencies in the 
genetic observations previously reported by others.
Serotonin Transporter
The serotonin transporter (5-HTT) plays an important role as 
a regulator of serotogenic signaling at synapses. The gene of 
serotonin transport (SLC6A4) is situated on chromosome 17 
(17q11.2); it has a common functional promoter polymorphism 
(5-HTTLPR, rs4795541), which consists of a short (S) and a long 
allele (L). The L allele of this marker has been found to transcribe 
the gene two to three times more efficiently than the S allele does 
(98). This candidate gene has been the subject of extensive study, 
and the results are divergent. Certain studies have reported an 
association of the S-allele with suicide (77, 78, 81), whereas other 
studies reported no significant difference (42, 80). The results of 
the Clayden et al. (46) meta-analysis of random-effects show that 
the minor (S) allele in SLC6A4 enhanced the risk of attempted 
suicide by 13% [OR = 1.13 (1.05–1.21), p = 0.001], with hetero-
geneity being low (I2 = 2,5%). A meta-analysis by Li and He (84) 
that comprised 39 studies suggests an association of the S-allele 
of 5-HTTLPR with SB.
When a pairing was made between suicide attempters and 
non-attempters who had the same psychiatric disorders, the 
carriers of the long allele (L) were found to be associated with 
reduced suicide risk (OR = 0.83; 95% CI: 0.73–0.95).
A meta-analysis of the results from 18 studies (83) failed to 
detect an association of 5-HTTLPR with SB. However, when 
the comparison only concerned patients diagnosed with the 
same psychiatric conditions, the frequency of the S-allele was 
found to be significantly more elevated in subjects having 
attempted suicide. Furthermore, it must be noted that several 
authors have reported an association of the S-allele with violent 
suicide (73, 78, 81, 83).
Hung et  al. (82) examined the link between the tri-allelic 
5-HTTLPR and SB among Chinese patients with schizophrenia 
and examined whether the use of violent methods in suicide 
attempts is influenced by the polymorphism. In their analysis, 
the authors used the LA-dominant model and found that the LA 
allele carriers were significantly more likely to have attempted 
suicide (p = 0.035); a comparable association was also reported 
between the LA allele and suicide attempts by violent means 
(p =  0.028). On the other hand, when the traditional biallelic 
5-HTTLPR was investigated, no association was detected. These 
results are different from those found in Caucasian subjects (79), 
for whom no associations have been identified.
Dopaminergic and Adrenergic Receptors
Dopaminergic Receptor
Suda et al. (99) conducted an investigation into two dopamin-
ergic D2 receptor (DRD2) genetic polymorphisms (TaqIA and 
-141C Ins/Del) in 120 Japanese suicide attempters and 123 vol-
unteers having no connection with them. The authors reported 
significant disparities between the suicide attempt group and 
the healthy control group (-141C Ins/Del, p =  0.01; TaqIA, 
p =  0.036) as regards the genotype and allele frequencies of 
polymorphisms. This result confirmed an earlier finding of an 
association between the DRD2-141C Del variant with suicide 
attempts in a group of German alcoholics (100). Studies of the 
AKT1 and AKTIP genes investigated the association of encod-
ing proteins, which are key to the identification of dopamine 
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and serotonin neurotransmitter systems, with SB observed 
in bipolar subjects. The results obtained showed AKT1 to be 
associated with cases of attempted suicide (rs1130214) and 
violent attack attempts (rs2494746) (101), but not AKTIP.
Adrenergic Receptor
The ADRA2A gene, composed of an intronless, single 3650-bp 
exon, is situated on chromosomes 10q24-q26, in other words, 
a region which has been found to be associated with attempted 
suicides independently of disease phenotypes (102). A number 
of genetic variants of the ADRA2A gene, including the promoter 
genetic variants N251K, have been reported to be associated 
with a tendency to completed suicide (103). However, Martín-
Guerrero et al. (104) failed to find any association of the N251K 
SNP with suicide completion. Using a case–control association 
study of 184 completed suicides and 221 control subjects in a 
Japanese population, Fukutake et al. (105) found that C-1291G 
SNP in the promoter region was significantly associated with 
suicide in females (p = 0.043 and 0.013 for genotypic and allelic 
comparisons, respectively).
Catabolism of Monoamines
Catechol-O-Methyltransferase
Catechol-O-methyltransferase (COMT) is encoded by a single 
gene that is localized on chromosome 22q11.1-q11.2 and 
represents a major enzyme in catecholamine inactivation. A 
common SNP, Val158Met in exon 4 of the COMT gene, has been 
observed as being linked to various psychiatric disorders, one 
of which being suicide (106). This SNP displays a commonly 
occurring functional polymorphism, a G to A nucleotide transi-
tion causing the substitution of amino acid from valine (Val) 
to methionine (Met) at position 158 COMT Val(108/158) Met 
(rs4680). This SNP (rs4680) affects the functional ability of the 
enzyme to catabolize synaptic proteins, such as that in human 
postmortem PFC tissue; the Val/Val genotype is associated 
with ~38% greater enzyme activity than that observed in Met/
Met homozygotes (107). Various studies have demonstrated 
associations of the COMT Val158Met gene polymorphism with 
SB (108, 109), although contradictory results have also been 
reported (110, 111).
A meta-analysis of six-related studies suggested an asso-
ciation of the COMT Val158Met polymorphism with SB, and 
this relationship was moderated by gender and the lethality 
of the suicide attempt (67). However, only two studies have 
been carried out to investigate the association of the COMT 
Val158Met polymorphism with completed suicides (108, 109). 
Pivac et al. (109) found significant disparities in how the COMT 
Val(108/158) Met variants (genotypes, alleles, and Val carriers) 
are distributed, but only in males, between suicide victims and 
controls (p = 0.018, p = 0.031, p = 0.005) and between violent 
suicide victims and controls (p = 0.026, p = 0.042, p = 0.010). 
Ono et  al. (108) found a significant difference between 
males having committed suicide and the male control group 
(p =  0.036), whereas occurrence of the high-activity COMT 
Val/Val genotype was significantly less frequent in males having 
committed suicide than in the male control group (OR: 0.52; 
95% CL: 0.31–0.89; p = 0.016).
In contrast, more recent meta-analyses that included new 
data questioned the association of COMT Val158Met with SB 
(111, 112) and did not report any association. Calati et al. (112) 
presented a revised meta-analysis of 12-related studies, with the 
authors failing to find any association of SB with rs4680 after 
consideration of both genotypes and the frequency of alleles. 
Further to that, the authors conducted a number of sensitivity 
and meta-regression analyses, designed first to consider ethni-
cally homogeneous groups; second, to compare suicide attempt-
ers vs. non-attempters in a cohort of subjects who were diagnosed 
with the same psychiatric conditions; and third, to explore the 
potential roles of gender and age as effect modifiers. No associa-
tion was found.
Monoamine Oxidase A
Monoamine oxidase A (MAOA), a mitochondrial outer mem-
brane enzyme, is known to cause neurotransmitter degradation, 
including that of dopamine, norepinephrine, and serotonin. The 
promoter region of the MAOA gene, itself situated on chromo-
some Xp21-p11, is polymorphic in terms of how many copies of 
a 30-bp repeat it has. The alleles observed for this upstream vari-
able number of tandem repeats (uVNTR) polymorphism include 
some with 3, 3.5, 4, and 5 repeats (3R, 3.5R, 4R, and 5R) (113). 
These uVNTR variants correspond to different transcriptional 
activities of the MAOA promoter, and these in turn give rise to 
varying expression levels of the MAOA gene.
A few recent studies have reported an association of the 
MAOA-uVNTR polymorphism with attempted suicide (114), 
while another study showed that there was a significantly higher 
frequency of the uVNTR two to three alleles in men who were 
violent suicide attempters than in those who were non-violent 
suicide attempters (115). We found more studies that did not 
show any association (42, 116). In the recent meta-analysis by 
Hung et  al. (117), after pooling data on 1452 subjects with SB 
and 1198 unaffected controls, the authors failed to find any 
significant disparity in the allelic distribution of the MAOA-
uVNTR polymorphism between subjects with SB and the male 
(OR = 0.85, 95% CI = 0.67–1.10, p = 0.22) or female controls 
(OR = 1.13, 95% CI = 0.94–1.36, p = 0.21). To better understand 
these divergent results, it is necessary to view them a new with a 
developmental approach. Indeed, in 2002, Caspi et al. (20) found 
that the MAOA-uVNTR polymorphism may reduce the risk 
of maltreated children growing up with increasingly antisocial 
behavior. Two other studies also find that SB might be influenced 
by the interaction between the MAOA-uVNTR polymorphism 
and trauma suffered in childhood (116). These various studies 
suggest that the MAOA-uVNTR genotype may not in itself exert 
an influence on SB but that it may interact with other environ-
mental elements to produce the complex behavior observed.
Hypothalamic–Pituitary–Adrenal Axis
Studies designed to investigate the supposed causes of a defective 
regulation of HPA axis in SB have focused principally on two 
factors: (i) glucocorticoid receptor feedback mechanisms and 
(ii) the corticotrophin-release hormone (CRH) signaling system 
(13). Association studies have mainly focused on the CRHR1, 
CRHR2, FKBP5, CRHR, CRHBP, and NR3C1 genes. Wasserman 
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et  al. (118) studied two polymorphisms in CRHR1 (rs1396862 
and rs4792887) and reported that the T-allele of rs4782887 con-
ferred a risk of attempted suicide (p = 0.002). De Luca et al. (119) 
studied a cohort of 231 schizophrenia sufferers, 81 of whom had 
made a suicide attempt, and found CRHBP to be associated at 
significant levels with attempted suicide (p = 0.035).
In a family-based association study model, using 660 nuclear 
family trios and 519 healthy controls Ben-Efraim et  al. (120) 
focused on the HPA axis and specifically on the role of the 
AVPR1B gene (arginine vasopressin receptor-1B) which was 
observed to associate with stress-related mood and anxiety 
disorders. In addition, they studied G × E interaction between 
AVPR1B variants and SLEs on any outcome. Their main results 
show a significant association (below the Bonferroni-corrected 
significance threshold of p = 0.0041) between variant rs33990840 
and 6-SNP haplotypes with suicide attempt (SA) but predomi-
nantly concurrent with high depressive symptoms. On the other 
hand, genetic associations with lifetime diagnoses of depression 
and anxiety in SA or G × E interactions between AVPR1B variants 
and SLEs (childhood/adolescence/adulthood physical assault or 
sexual assault, and high lifetime SLEs) were not significant. An 
exploratory screen of interactions between AVPR1B and CRHR1 
showed no support for gene–gene interactions on the studied 
outcomes.
Genes Involved in Neurotrophic Processes
Several lines of evidence from postmortem studies and expression 
studies indicate that brain-derived neurotrophic factor (BDNF) is 
a good candidate gene for involvement in SB (121). Further atten-
tion has been given to the Val66Met (rs6265) polymorphism in 
genetic studies of suicide. This particular polymorphism is an SNP 
in the BDNF gene, and it produces a valine (Val) to methionine 
(Met) substitution at codon 66 in the prodomain (BDNFMet).
We have listed a number of studies showing associations 
between Met allele and SBs in the context of various psychiatric 
diagnoses, including schizophrenia (122), bipolar disorder (123, 
124), and depression (125, 126), and in several ethnic groups 
(Caucasian, Japanese, and Chinese). Table  3 summarizes the 
main selected studies.
For example, a Slovenian team demonstrated the association 
between BDNF rs6265 polymorphism and suicide in a cohort 
of subjects with completed suicide (133). In the second part, 
this same team expanded their study by investigating several 
additional SNPs in the BDNF gene (rs7124442, rs10767664, 
rs962369, rs12273363, rs908867, rs1491850, and rs1491851). 
In this classic conception, the authors evaluated the differences 
in the allele, genotype, and haplotype frequency distributions 
of these seven SNPs between suicide completers and control 
subjects.
The control group was made up of subjects who died of 
natural causes or in road accidents. The authors were only able 
to demonstrate a statistical difference in haplotype analyses. 
The haplotype C–A–T–T–C was significantly associated with 
completed suicide. Additionally, single-marker analysis under 
four inheritance models with the adjustment for potential 
confounders, like age, gender, or alcohol dependence syndrome 
status also failed to reveal any associations. The diathesis–stress 
model is often used to include the biological and environmental 
contributions to SB, where the stressor is an environmental fac-
tor such as childhood abuse, substance abuse, or the experience 
of psychiatric illness. It is an approach which we have mentioned 
several times. The study by Perroud et  al. (129) examined the 
interaction between BDNF rs6265 and a history of childhood 
sexual abuse and found that violent suicide attempts were associ-
ated with childhood sexual abuse only in those adults with a 
Val/Val genotype at rs6265. Sarchiapone et al. (126) found that 
the risk of a suicide attempt was significantly higher among 
depressed patients reporting higher levels of childhood emo-
tional, physical, and sexual abuse.
More recently, Zouk et al. (66) found an association between 
genotype allele GA in rs4923463 and violent suicide attempt 
(p =  0.03) in patients with bipolar disorder. The other studied 
polymorphisms, including rs6265 (Val66Met), were not associ-
ated with any comorbidity. Further studies failed to report that 
Val66Met was associated with suicide attempt (131, 132). Zarrilli 
et al. (131) performed postmortem genotyping on 512 individu-
als, 262 of whom had committed suicide. There was no statisti-
cally significant difference between the level of the Met allele in 
the completed suicides compared to the controls. However, it 
should be noted that the authors do not specify the psychiatric 
characteristics of the cases and the controls. This may affect the 
results and influence the interpretation of the results.
Zai et al. (137) carried out the first meta-analysis of the func-
tional BDNF marker Val66Met (rs6265, 196G > A) in SB, using 
data from 12 studies (total n = 3352 subjects, of whom 1202 had 
a history of suicide). This meta-analysis revealed a trend whereby 
the Met  allele and Met-carrying genotypes conferred a risk of 
suicide (p = 0.032; ORMet = 1.16, 95% CI 1.01–1.32).
Working with a cohort de 130 multiplex bipolar pedigrees 
(n  =  795), Sears et  al. (130) found seven SNPs of CCKBR 
(rs2941025, rs2929183, rs2941023, rs2947025, rs2941029, 
rs2947029, and rs2947028) which were associated with suicide 
attempt and which remain significant after correction for multiple 
testing. No variant of the BDNF gene reaches the amended sig-
nificance threshold (p ≤ 0.00156). This result is in contradiction 
with other case–control type studies and with the meta-analysis 
by Zai et al. (137) which were described earlier, in the BDNF sec-
tion. The study by Sears et al. (130) has the advantage of having 
studied several BDNF polymorphisms, whereas the majority of 
other studies only tested the Val66Met SNP. The “cases” are all 
from a cohort of patients with bipolar disorder, which poses the 
question as to whether the significant CCKBR polymorphisms 
might be associated with bipolar disorder and not with suicide 
attempts. The authors point out that the SNPs tested had been 
previously studied in another cohort of bipolar patients and that 
no association with bipolar disorder had been found.
Recently, Ratta-Apha et al. (136) performed a meta-analysis 
that included six studies using Asian subjects (122, 123, 125, 127, 
128, 136). The results demonstrated that the Met-allele had a 
tendency to be associated with the risk of suicide attempt (num-
ber of Met-alleles = 437: total number = 1.428, pool OR = 1.37, 
95% CI =  1.01–1.86, Z-value =  2.047, p =  0.041). However, a 
meta-analysis that included three studies that used completed 
suicide as subjects (131, 133, 136) failed to show an association 
TABLe 3 | Details of studies included in the review for neurotrophic factor gene.
Reference variants Suicide outcome/
diagnosis
Sample investigated Findings Populations
Brain-derived neurotrophic factor (BDNF) and other neurotrophic factors
Hong et al. (127) Val66Met SB-mood disorders 67 SB+ vs. 125 SB− No association Chinese
Hwang et al. (128) Val66Met SA-MDD (elderly 
inpatients)
22 SA+, 88 SA−, 171 
controls
No association Chinese
Iga et al. (125) Val66Met SA-MDD 23 SA+ vs. 131 SA− Met66 allele carriers were more likely to have SB Japanese
Huang and Lee (122) Val66Met SA-schizophrenia 16 SA+ vs. 116 SA− Met/Met patient were more likely to have SB Asian
Sarchiapone et al. (126) Val66Met SA-depressive 
disorders
97 SA+ vs. 73 SA− A allele (AA + GA) * SA (65.3% vs. 50.5%; p = 0.05) Caucasian 
(Slovenia)
Vincze et al. (124) Val66Met +  
3 SNPs
SA-bipolar disorders 176 SA+, 254 SA−,  
370 controls
Val66 allele is risk allele for violent suicide attempt 
(p = 0.01)
Caucasian 
(France, 
Suisse)
Kim et al. (123) Val66Met SA-bipolar disorders 43SA+ vs. 126 SA− Met/Met patient were more likely to have SB Asian
Perroud et al. (129) Val66Met SA-psychiatric 
patients
615 SA+ non-violent, 
198 SA+ violent
Val–Val genotype increase risk for violent attempt Caucasian 
(France, 
Suisse)
Sears et al. (130) Val66Met +  
31 SNPs
SA-bipolar disorders 130 multiplex bipolar 
pedigrees, n = 795
7 SNPs of CCKBR* SA (p corr. < 0.05) New Zealand
Zarrilli et al. (131) Val66Met Completed suicide 262 vs. 250 controls No association Caucasian 
(Slovenia)
Kohli et al. (132) 83 SNPs 
(NTRK2 and 
BDNF)
SA-depressive 
disorders
Discovery sample: 
113 SA+, 366 SA− 
replication sample: 
152 SA+, 592 SA−
rs11140714 (NTRK2) * SA p = 2.6 × 10−4 
(p corr. = 0.043) and p corr. < 0.05 in replication 
sample. BDNF No association
African-
American, 
German
Zouk et al. (66) Val66Met + 3 
SNPs
SA-bipolar disorders 74 SA+ vs. 86 SA− rs4923463 (G/G) * violent SA (p = 0.03) Brazilian
Pregelj et al. (133) Val66Met Completed suicide 359 vs. 201 controls Met/Met and Met/Val genotypes are risk factors for 
violent completed suicide in female
Caucasian 
(Slovenia)
Strauss et al. (134) 10 SNPs 
(HOMER, 
NPTX) 
SA-mood disorders 105 SA+ vs. 96 SA− HOMER1 rs2290639* SA, NPTX2 rs705315, 
rs1681248 *SA (p corr. < 0.05)
African-
American, 
European-
American
Ropret et al. (135) Val66Met + 7 
SNPs
Completed suicide 486 vs. 289 controls Haplotype C-A-T-C-C is risk haplotype for completed 
suicide
Caucasian 
(Slovenia)
Ratta-Apha et al. (136) Val66Met + 6 
SNPs
Completed suicide 307 vs. 380 healthy 
controls
No association Various
Zai et al. (137) Val66Met SA-meta-analysis 8 studies: 433 cases,  
1371 controls
OR Met-carrier = 1.25 (1.06–1.49) p = 0.008 OR 
Met = 1.22 (1.06–1.41) p = 0.006
Various
Clayden et al. (46) Val66Met SB-meta-analysis 7 studies: 1700 cases, 
2548 controls
No association Various
Ratta-Apha et al. (136) Val66Met CS-meta-analysis 3 studies: 921 cases,  
825 controls
No association Various
Ratta-Apha et al. (136) Val66Met CS-meta-analysis 6 studies: 471 cases,  
967 controls
No association Asian
CS, completed suicide; MDD, major depressive disorder; SA, suicide attempt; SA+, suicide attempters; SA−, patient without a history of suicide attempt; SB, suicidal behavior;  
SI, suicide ideations; SNP, single-nucleotide polymorphism.
*Associated with.
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of the Met-allele with a risk of completed suicide (number of 
Met-alleles in completed suicide =  515: total number =  1.746, 
pool OR = 1.03, 95% CI = 0.88–1.19, Z-value = 0.315, p = 0.753).
With respect to the NTKR2 gene, Kohli et al. (132) showed 
an association of five tagging SNPs that are located within the 
NTRK2 locus with a lifetime history of SB within depressed 
patients in two independent German samples. On the other 
hand, the authors did not find any association with regard to 
BDNF. Perroud et  al. (88) investigated the genetic predictors 
of an increase in suicidal ideation during the treatment of 796 
adult subjects suffering from major depression who were treated 
with escitalopram or nortriptyline in Genome-based Therapeutic 
Drugs for Depression (GENDEP). The strongest association was 
detected for a SNP known as rs962369 in BDNF (p = 0.0015). 
In addition, a significant interaction was reported between the 
variants of BDNF and NTRK2 (p = 0.0003).
Strauss et al. (134) studied two genes that appear to be involved 
in neuroplasticity: HOMER1 and human neuronal pentraxin II 
(NPTX2). Their population is different from that of others because 
they focused on subjects who developed childhood-onset mood 
disorders (COMDs). This population is at high risk of SA and 
suicide. In their analyses, they made comparisons within the 
COMDs group and then compared the total COMD sample with 
healthy controls. After correction for multiple testing, none of 
the markers studied was significantly associated with COMDs. 
However, in the COMDs group, the authors report association 
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between SA and HOMER1 rs2290639 genotype, as well as 
between SA and NPTX2 rs705315 and rs1681248 genotypes. The 
results should be interpreted with caution, given the stratification 
of the population. Indeed, the authors found more SA among 
African-Americans than in European-Americans. For example, 
rs2290639 is monomorphic for the A allele in HapMap YRI 
(African) sample, but not in the CEU (European) sample. As a 
result, the reduction in the risk of SA observed by the authors in 
heterozygous carriers of rs2290639 may be related to European-
American ancestry.
Others Genes
In a population made up of 660 trios, Sokolowski et  al. (138) 
reported several associations and linkage of SNPs in the GRIN2B 
and ODC1 genes with suicide attempt. In their haplotypic analysis 
of GRIN2B, the best significant results showed over-transmission 
for six haplotypes (all p < 4.0 × 10−4) of four to seven SNPs in 
length, all containing the minor risk C allele of SNP rs2268115. 
As in the study by Ben-Efraim et al. (74), the authors investigated 
G × E interactions, and especially physical and sexual abuse. In 
their analyses of G × E, the authors did not find significance for 
the GRIN2B or ODC1 SNPs which had shown direct genetic asso-
ciations. However, one significant G × E was revealed between a 
third ODC1 SNP (rs7559979) and childhood/adolescent physical 
assault (p < 10−4).
Laje et al. (139) reported two other glutamatergic genes (GRIA3 
and GRIK2) in relation to TESI. Similarly, a different study asso-
ciated polyaminergic single-nucleotide polymorphisms explicitly 
with SBs (95).
In a sample of 77 trios (suicide attempters and both their 
parents), Wasserman et al. (140) investigated 250 genetic markers 
using TDT analysis. The authors showed that gene variants in 
the sodium channel, voltage gated, type VIII, alpha polypeptide 
(SCN8A) (p =  0.008), vesicle-associated membrane protein 4 
(VAMP4) (p = 0.004), and prenylated Rab acceptor 1 (RABAC1) 
(p =  0.006) genes are over-transmitted in suicide attempt. In 
an independent replication sample comprised of 190 trios, the 
authors confirmed the data for the SCN8A (p  =  0.005) and 
VAMP4 (p = 0.019) genes.
Association Studies in Adolescent 
Population
Although SB is an important public health issue, few studies 
have been devoted to its genetic aspects. However, the hereditary 
component of SBs in adolescents has been well identified. The 
study by Brent et  al. (5) is a reference in this field. This team 
studied the relatives of 58 adolescent suicide probands and 55 
demographically similar controls. They clearly show that the rate 
of suicide attempts was increased in the first-degree relatives of 
suicide probands compared with the relatives of controls, even 
after adjusting for differences in rates of proband and familial 
Axis I and II disorders (odds ratio, 4.3; 95% confidence intervals, 
1.1–16.6). We identified only very few studies devoted to the ado-
lescent population. One possible reason for this is the difficulty of 
obtaining genetic research consents for minors. Two teams in the 
world have published several articles, the Zalsman et al. (34, 68, 
72) and the Brent et al. (15) teams.
The oldest study we identified goes back to 2001 (34). Given 
the small number of studies, we have deliberately chosen to 
include it in our review. Zalsman et al. (34) attempted to clarify 
the role of the A218C polymorphism in intron 7 of the TPH 
gene. The family-based method, among others, was used, so as to 
limit the difficulty of sampling for the control group, in a cohort 
of 88 teenagers (of Ashkenazi Jewish origin) hospitalized for a 
suicide attempt. Allele frequencies were calculated and tested for 
association to phenotype using the HRR and TDT methods. The 
authors show that there was no significant allelic association of 
A218C polymorphism with suicide attempt or other phenotypic 
measures according to the HRR method (chi-square =  0.094; 
p = 0.76) and the TDT method (chi-square = 0.258; p = 0.61). In 
the same population, Zalsman et al. (68) tested T102C polymor-
phism (5-HTR2A gene) without demonstrating any significant 
association in allelic distribution between transmitted and non-
transmitted alleles. Similarly, there was no significant associa-
tion of genotype with any of the clinical traits. The same team 
conducted a case–control association study (72) in four groups of 
adolescents: (i) suicidal psychiatric inpatient adolescents (N = 35), 
(ii) non-suicidal psychiatric inpatient adolescents (N = 30), (iii) 
adolescents admitted to psychiatric emergency rooms due to a 
suicide attempt (N =  51), and (iv) a community-based control 
group (N = 95). The authors found that homozygosity for T (TT) 
of the HTR2A 102T/C polymorphism is associated with lower 
impulsivity (p = 0.03) and aggression (p = 0.01) compared with 
TC carriers and that a low activity MAOA was significantly asso-
ciated with suicidality (p = 0.04). However, their analyses found 
no significant association between alleles of 5HTTLPR gene and 
suicidality.
Studying a subsample of adolescent depression (n  =  155) 
sufferers who participated in the Treatment of SSRI-Resistant 
Depression in Adolescents (TORDIA) trial, Brent et  al. (15) 
found that two polymorphisms in FKBP5 (rs1360780TT and 
rs3800373GG) were linked to suicide events (n = 18), even when 
they controlled for related covariates and treatment effects. Even 
though the number of suicidal events remains low, the authors 
correctly described the sample, the suicidal events were well char-
acterized, and the effects of the treatment were taken into consid-
eration in the analysis. In addition, this study is interesting from a 
pathophysiological point of view because the FKBP5 gene codes 
for a protein that decreases the sensitivity of the glucocorticoid 
receptor to the effect of corticosteroids. This result is consistent 
with previous studies linking SB with the insensitivity of the HPA 
axis to feedback and increased secretion of cortisol (94).
In summary, despite some interesting leads, the results all 
point to the same conclusions as in the adult population: no 
specific locus significantly associated with SBs has been identified 
so far, even when family-based methods are used.
Genome-wide Association Study
The use of association for the fine-mapping of candidate regions 
from linkage studies quickly gave way to more general or GWAS. 
One of the greatest benefits of GWAS is that it is “agnostic” or 
based on no prior assumptions. Usually, a simple regression 
analysis is used to systematically test each biallelic SNP across the 
genome for association with a trait or disease. Many generations 
TABLe 4 | Details of studies included in the review for genome-wide association study.
Reference Nb of SNPs Sample investigated Suicide outcome/diagnosis Findings
Laje et al. (90) 109,365 n = 180, 90 cases TESI: MDD rs11628713** (PAPLN)
rs10903034* (IL28RA)
Perroud et al. (88) 539,199 n = 706, 244 cases TESI: MDD rs11143230* (GDA)
rs358592* (KCNIP4)
rs4732812* (ELP3)
Menke et al. (89) 371,335 n = 397,32 cases TESI: bipolar disorder rs1037448* (TMEM138)
rs10997044* (CTNNA3)
rs1109089* (RHEB)
Perlis et al. (144) 1.9 × 10−9 n = 8737, 2805 cases SA: MDD MDD: rs2576377*** (ABI3BP)
SA: bipolar disorder (BD) BD-MDD: rs4918918* (SORBS1)
SA: MDD or BD BD-MDD: rs10854398* (B3GALT5)
BD or MDD: rs1360550* (PRKCE)
Schosser et al. (146) 532,774 n = 2023, 251 cases SA: MDD rs4751955* (GFRA1) (Suicidality score)
rs203136* (KIAA1244) (SA)
Willour et al. (145) 730,000 n = 5815, 2496 cases SA/MDD rs300774*** (2p25; ACP1, SH3YL1, FAM150B)
Galfalvy et al. (147) 37,344 n = 99,68 cases Completed suicide 58* SNPs (19* genes)
Mullins et al. (148) 532,774 n = 3270, 426 cases SA: mood disorders No association
Galfalvy et al. (149) 1,014,770 n = 1810, 577 cases CS and SA: psychiatric patients 15 SNPs* (STK3, ADAMTS14, PSME2, TBX20)
Zai et al. (150) ~1 million n = 959 cases SB (suicide severity scale): BD rs10448042*, rs10448044* (IL7)
rs3851150*, rs7244261* (TMX3)
Sokolowski et al. (151) ~1 million 660 nuclear family trios SA-psychiatric patients SNP-by-SNP GWAS: no association
Polygenic associations: 750
Neurodevelopmental genes (p corr. < 0.05)
CS, completed suicide; MDD, major depressive disorder; SA, suicide attempt, SA+, suicide attempters; SB, suicidal behavior; SI, suicide ideations; SNP, single-nucleotide 
polymorphism.
*Suggestive association p < 10−5.
**Genome-wide significant alpha 0.05 by experiment-wide correction.
***p < 5 × 10−8, genome-wide significant at alpha 0.05.
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of recombination create smaller regions of LD, which (with 
dense enough marker coverage) provides a substantially higher 
resolution than linkage and the potential to tag common causal 
variants (141). Researchers must make sure that the associated 
loci are not spurious associations which are due, for example, to 
population substructure or admixture (142). The use of hundreds 
of thousands of markers also necessitates very strict significance 
criteria, which makes it difficult to detect all but the largest effects. 
Li et al. (143) suggested that a p-value threshold of ~10−7 should 
be used as the genome-wide significance criterion for the earlier 
commercially available genotyping arrays, but marginally more 
rigorous p-value thresholds ~5 × 10−8 for more recent or merged 
commercially available genotyping arrays, ~10−8 for all the most 
frequent SNPs in the 1000 Genomes Project dataset and ~5 × 10−8 
for the common SNPs only within genes.
We identified 11 GWAS. Table 4 summarizes the main results. 
Among these studies, we found three studies that focused on 
treatment emergent or treatment worsening suicidal ideation in 
patients who were taking antidepressant drugs (88–90) and eight 
GWAS (144–151) that were focused on suicidality in behavioral 
domains (suicide attempts or completed suicides).
Laje et  al. (90) followed up with the first GWAS in patients 
from the STAR*D clinical trial using the Illumina Human-1 
BeadChip that samples 109,365 SNPs. One SNP (in PAPLN) was 
genome-wide significant (corrected p = 0.01, odds ratio 4.9), and 
another SNP (in IL28RA) was reported as suggestive.
Perroud et al. (88) published a GWAS of suicidality associated 
with treatment in the GENDEP 706-strong sample of patients 
being treated for major depression with either nortriptyline or 
escitalopram. The genetic marker that was found to have the 
most significant association with an increased level of suicidality 
(8.28 ×  10−7) proved to be a single-nucleotide polymorphism 
(rs11143230) that was located 30 kb downstream of a gene that 
encoded guanine deaminase (GDA) on chromosome 9q21.13. 
In addition, treatment-specific SNPs (rs358592 in KCNIP4, 
rs4732812 near ELP3), drug  ×  treatment interaction SNPs 
(rs1368607, rs2707159 in APOO gene, rs284668 near p53AIP1/
RICS genes) together with a number of genes (in NTRK2, CCK, 
YWHAE, SCN8A, and CRHR2) from an additional candidate–
gene analysis were all reported as suggestive associations. Menke 
et al. (89) carried out a GWAS on TESI, over the initial 12 weeks 
following treatment with various SSRIs in GSK-Munich and 
Munich Antidepressant Response Signature (MARS) cohorts. The 
discovery sample failed to show any association at significance 
level, whereby 79 suggestive SNP associations with the lowest 
p-values were instead used for testing in an independent replica-
tion sample. Following this two-phase analysis, 14 SNPs were 
reported to be suggestive, of which 6 SNPs were in high LD. These 
could be annotated to five distinct genes (TMEM138, CTNNA3, 
RHEB, CYBASC3, and AIMI), and the other three SNPs had 
an intergenic location. One SNP in GDA [a gene proposed in 
the Perroud et al. GWAS (88)] had a suggestive association with 
TESI, together with other candidate genes for neuro-psychiatric 
disorders (FKBP5, ABCB1).
In 2010, Perlis et  al. (144) tested almost 2 million common 
genetic variants for association with a history of suicide attempts 
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among 5815 individuals with bipolar disorder and 2922 individu-
als with major depression. In the bipolar cohort, they found five 
loci that included SNPs with a p value of <1 × 10−5, but none of 
them had a nominal p value of <0.05 in the cohort of bipolar 
disorder replication subjects. Among 1273 subjects with major 
depression, 6 loci had SNPs with a p value of <1 × 10−5; the mini-
mum p value was 2.55 × 10−8 (rs2576377 in gene ABI3BP). But 
none of these regions had a p value of <0.05 in a second depression 
cohort. Furthermore, the authors examined association results 
in 19 genes that were previously suggested to be associated with 
suicide attempts. The two genes FKBP5 and NGFR (p75NTR) 
offered nominal evidence of association in bipolar disorder 
patients (uncorrected, p < 0.05) but which failed to persist after 
correction for 19 comparisons.
Schosser et al. (146) did not find any evidence for significant 
association at genome-wide level, and the strongest results 
in their study were not replicated in analysis of independent 
MDD cohorts with a similar assessment of SB. Their analysis of 
the candidate gene yielded some evidence of a polymorphism 
(rs10868235) in NTRK2 which had already been found to be 
associated with suicidality.
Willour et  al. (145) reported a GWAS that compared SNP 
genotypes of 1201 bipolar (BP) suicide attempters with the geno-
types of 1497 BP patients with no history of attempted suicide. 
After correction for multiple testing, none of the results from the 
replication sample had any significant association. On the other 
hand, an integrated meta-analysis investigation of both types 
of sample (discovery and replication) produced a significant 
genome-wide association for SNP rs300774.
The marker with the most significant association was rs300774 
in an intergenic region at chromosomal region 2p25 containing 
the SH3YL1, ACP1, and FAM150B genes.
Galfalvy et al. (147) conducted a first study on completed sui-
cides; sudden non-suicide-related deaths were used as controls. 
Their pilot study, which sought to identify candidate–gene regions 
that were associated with susceptibility to suicide, independently 
of the associated psychiatric diagnosis, found 22 SNPs in 19 genes 
using an SNP chip. Importantly, the majority of these genes have 
never been studied previously, and for many, their functions are 
unknown.
Mullins et  al. (148) carried out GWAS and made the first 
application of polygenic score analysis to four patient cohorts 
with mood disorders, in an attempt to identify common genetic 
variants for mood disorders and SB. They used SNPs from 
three GWAS discovery studies of attempted suicides (BACCs, 
GSK-Munich, RADIANT), from one study of suicidal ideation 
(GENDEP) and from three studies of psychiatric disorders (PGC-
MDD, PGC-BIP, and PGC-SCZ), in order to calculate polygenic 
scores for individual subjects in four validation datasets. They 
failed to detect any significant association evidence for any SNP 
in the GWAS or meta-analysis.
Galfalvy et  al. (149) conducted a GWAS on completed 
suicides and patients having a history of attempted suicide 
with non-fatal outcome (n =  577) compared with psychiatric 
control and healthy volunteer groups (n =  1233). They used 
logistic regression to test association with genotype–SB. No SNP 
attained genome-wide significance in their study, but a number 
of SNPs in the ADAMTS14, STK3, TBX20, and PSME2 genes 
reached p <  1 ×  10−5. They concluded that the most plausible 
candidate genes, ADAMTS14, PSME2 (both of them associated 
with inflammatory response), and TBX20 (brainstem motor 
neuron development), had not before been identified as being 
associated with SB.
Zai et  al. (150) conducted a GWAS study of the severity of 
SB (from suicidal ideation to serious suicide attempt) using 
three independent BD samples and failed to detect significant 
genome-wide association of any of the markers tested in any of 
the BD samples. They identified markers in two chromosomal 
areas that were suggestively associated with suicide severity in 
bipolar patients (chromosome 8q12, near the proenkephalin 
gene PENK). The second stretch is located at chromosomal posi-
tion 10p11.2, which contains the genes coiled-coil domain that 
contains 7 (CCDC7). As well as conducting GWAS of suicide 
severity, the authors carried out a GWAS of attempted suicides 
in three BD samples. They identified two regions of suggestive 
associations. The first region was localized to 8q12-q21 and was 
~400  kb upstream of the interleukin 7 (IL7) gene. The second 
region was ~150  kb downstream of the thioredoxin-related 
transmembrane protein 3 coding TMX3 gene in 18q22.
Finally, the study by Sokolowski et  al. (151) attempted to 
take account of the shortcomings of the earlier studies. With 
the major problem of GWAS being their low statistical power, 
the authors used the polygenic risk score (PRS) developed by 
Purcell et al. (152) PRS can show strong associations for many 
SNPs with small effects, and, in some cases, with small samples. 
PRS has also been used by Mulins et al. (148) to provide data 
concerning genetic overlap between different psychopatholo-
gies. To increase power, the authors used an a priori assumption 
with different genomic SNP subsets. The cases of SA were well 
identified from a cohort of 660 trios (nuclear family trios – all 
complete with both biological parents and one SA offspring per 
trio). The authors thus conducted the first-ever family-based 
GWAS. First, they performed a traditional SNP-by-SNP-based 
GWAS and they failed to reveal any significant genome-wide 
associations with SA. Similarly, when they focused on the 10 
genes suggested in three previous GWAS on SB for follow-up 
(ABI3BP, B3GALT5, PRKCE, SORBS1, ACP1, KIAA1549L, 
LRRTM4, TMEM132C, GFRA1, and KIAA1244), no significant 
association was identified.
Second, the authors conducted PRS tests with several sources 
from the Psychiatric Genomics Consortium, and a PRS that was 
discovered and validated in the Genetic Investigation of Suicide 
and SA (GISS) revealed the polygenic association of SNPs in 750 
neurodevelopmental genes, which was driven by the SA pheno-
type, rather than the major psychiatric diagnoses. Several results 
are worth noting: (i) the authors found evidence for polygenic 
associations of SNPs in neurodevelopmental genes in the SA 
subjects (even in the absence of major psychiatric diagnoses). 
(ii) The SCZ polygenes showed overlap with SA, and the degree 
of overlap depended on the presence or absence of diagnoses. 
(iii) The extended major histocompatibility complex region 
did not contribute to the overlap, but the authors delineated 
the genetic overlap to neurodevelopmental genes that partially 
overlapped with those identified by the GISS PRS. Among the 
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590 SA polygenes implicated here, there were several develop-
mentally important functions and 16 of the SA polygenes have 
previously been studied in SB [BDNF, CDH10, CDH12, CDH13, 
CDH9, CREB1, DLK1, DLK2, EFEMP1, FOXN3, IL2, LSAMP, 
NCAM1, nerve growth factor (NGF), NTRK2, and TBC1D1]. 
These results, at genome-wide level, emphasize the importance 
of a polygenic neurodevelopmental etiology in SB. This is true 
not only for SBs but also for some other psychiatric disorders, 
especially in children and adolescents, for whom a developmental 
and integrative approach is essential.
DiSCuSSiON AND CONSiDeRATiONS 
FOR FuTuRe DiReCTiONS
Summary of the Current Review
Over the last decade, many teams from around the world have 
attempted to identify associations between genetic markers and 
SBs. It is recognized by all that single genes might not explain the 
full risk of developing SBs. In summary, we have identified several 
studies that have shown an association of genetic polymorphisms 
with SBs, in line with previous reviews (31–33). The strongest 
results from meta-analyses support the combination of SB with 
variants in TPH1-rs1800532 (43, 46, 84), SLC6A4-5-HTTLPR- 
(46, 84), COMT-rs4680-(67) or BDNF-rs6265 (137).
Results to date from GWAS are unsatisfactory, with most 
studies showing no evidence of association at genome-wide sig-
nificant level (89, 145, 147–149) or only marginally (90, 146, 150). 
Studies which did show an association (p < 5 × 10−8) (88, 144) 
failed to replicate the results.
Several pathways have been mentioned in an attempt to 
understand the lack of reproducibility and disappointing results. 
Consequently, we shall now review and discuss the following: 
(i) sample characteristics and confounding factors; (ii) statistical 
limits; (iii) gene–gene interactions; (iv) gene, environment, and 
by time interactions; and (v) technological and theoretical limits.
Sample Characteristics and 
Confounding Factors
The ability to identify significant associations and the relevance 
of such information to suicidality is linked both to the number 
of subjects in each group and to the method used to define the 
groups. Although the family transmission of suicidality would 
tend to suggest that suicide is a separate phenomenon from 
psychopathology (10), there is need to carefully control biologi-
cal factors that are associated with psychopathology, and this is a 
process which poses significant methodological and operational 
challenges. Several diagnoses frequently associated with suicide 
like, for example, bipolar disorder, major depression, schizo-
phrenia, or alcoholism, have been routinely included in studies 
curried out thus far, and use has been made of various methods to 
distinguish their effects from those linked to suicide. In contrast, 
axis II has rarely been considered, and it appears to be a confusing 
factor, considering the importance of personality traits such as 
impulsivity/aggressiveness.
Turecki (18) suggested that the studies having the best chance 
of properly controlling psychopathology were those which, 
within psychopathological groups, compared subjects who 
committed suicide with those whose death was due to another 
cause. However, it poses a considerable operational challenge to 
constitute a control group of subjects suffering from psychopa-
thology which is comparable to the suicide group with respect to 
a number of other variables.
Second, variations in the definition of SB in the studies on 
genetic association are considerable, a fact which would tend 
to render comparisons between the results obtained somewhat 
rash. The definition of suicidal ideation includes suicide threats or 
thoughts that produce no action, and the precise clinical defini-
tion of the concept is still inadequate and confusing. A number 
of studies offer evidence showing that suicidal ideation is very 
different, in terms of phenotype, from suicide attempt. An excess 
level of suicidal ideation was observed in the family environment 
of suicide victims, but it was not found to be significant once 
adjustments were made to take account of psychiatric disorders 
(5). The suggestion has been made that ideation might coseg-
regate with psychiatric disorders, while the tendency to move 
from ideation to action is, at least to some extent, the result of 
a different genetic diathesis (91). The logical conclusion would 
seem to be that molecular genetic studies on attempted suicide 
cases should not seek to address the concept of suicidal ideation.
Some have proposed the use of eminently heritable phenotypes 
in genetic analyses as being the most promising way of identifying 
real genetic associations. A strategy of heritable intermediate phe-
notypes (endophenotypes) has been proposed by the American 
Foundation for Suicide Prevention (91). A number of promising 
endophenotypes that have been put forward for genetic studies 
on suicide include traits of aggression/impulsivity. However, the 
choice of such suicidality-related phenotypes is not a light matter.
Statistical Limits
In the genetics of complex disease, it is necessary to limit both 
type I and type II errors. The value of studies concerned with 
allelic association is mainly a function of the size of the samples, 
the effect size of the susceptibility loci, how strong the linkage 
disequilibrium with a marker is, and how frequently susceptibil-
ity and marker alleles occur. Multiple testing, the rates of false 
positives and statistical significance levels are important issues 
in genetic association studies. Several statistical techniques are 
being developed for multiple comparison correction, but the 
ability to replicate findings of genetic associations in unrelated 
population samples is still the ultimate benchmark for complex 
disease genetics (153). GWAS picks up on alleles in the popu-
lation which occur commonly, but which are each unlikely to 
have more than a very slight incidence on what is a complex 
phenotype (154).
Simultaneously investigating thousands of SNPs, which indi-
vidually do not reach significance, could explain a greater amount 
of the heritability. To increase the power to identify disease 
variants, several genetic markers could be studied simultaneously. 
The cumulative genetic effect of multiple SNPs is more likely to 
have a higher heritability than any of the individual SNPs. Other 
methods have been proposed, including global haplotype tests, 
regression methods, and multimarker tests; these tests address 
multiple testing by combining multiple SNPs into a single test 
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(155). Polygenic score analysis has recently generated much 
interest for assessing the explanatory power of an ensemble of 
markers. A GWAS is conducted on an initial training sample, 
and the markers are ranked by their evidence for association, 
usually their p-values. An independent replication sample is then 
analyzed by constructing, for each subject, a polygenic score con-
sisting of the weighted sum of its trait-associated alleles, for some 
subset of top ranking markers (156). This approach has been used 
by the Psychiatric Genomics Consortium and the International 
Schizophrenia Consortium to investigate major depression and 
schizophrenia (157). This recent method could explain a larger 
component of the heritability of SB than would individual alleles 
that each has small effect sizes.
Gene, environment, and by Time 
interactions
Gene–environment interactions might to some extent account for 
variations in the link between the experience of stressful events 
and the emergence and severity of a given major depression 
and SB episode in young subjects. For example, the well-known 
study by Caspi et al. (20) showed that depression accompanied 
by suicidal ideation or attempted suicide is to be predicted in 
children, adolescents, and young adults who are carriers of the 
S allele of the 5-HTTLPR polymorphism. This pattern involves a 
complex area of research because it is difficult to understand the 
impact of the environment. However, several studies have shown 
interesting results, mainly those who have considered adverse life 
events (19). Moreover, age appears to also be a factor that has not 
sufficiently been taken into consideration. Studies that used MRI 
and fMRI showed both alterations related to age and differences 
related to gender in gray and white matter over the period of 
adolescence (158). These results could go some way to explain-
ing why a large number of psychiatric disorders, including SB, 
manifest themselves during this period of life and might explain 
the gender-related differences seen in adolescent SB, namely that 
females have a greater tendency to attempt suicide than males, who 
tend to achieve completed suicide more frequently. Zalsman et al. 
(72) suggested that the fact of restricting the investigation of SB in 
adolescents simply to the interaction between gene and environ-
ment might prevent researchers from detecting other complex 
interaction factors, which involve timing. It seems legitimate to 
speculate that it is only when particular genotypes are exposed 
to specific environment-related risks during a critical period of 
brain development that suicidality would be the outcome.
Gene–Gene interactions
A reason that is frequently given to explain why genetic stud-
ies of complex diseases have met with such scant success is the 
interactions which have been observed to exist between loci. 
Given that there is recognition of the complexity of the genetic 
architecture, with several levels of interaction, the fear is that 
the effect will be missed if one examines it in isolation, without 
taking into account the possible interactions it may have with 
the other factors. Various methods and software packages have 
therefore been designed to take account of statistical interac-
tions between loci in the analysis of data provided by studies 
of genetic association. In a large review, Cordell (159) offers a 
critical survey of the methodological approaches (with the 
associated software) which are in current use for the detection 
of interactions between genetic loci identified as contributing to 
genetic disease in humans. She concludes that, even though the 
exact details of the methodologies may differ, there are, in many 
instances, tight conceptual links between the various approaches, 
and a correct apprehension of such links can perhaps best be 
obtained through an improved understanding of the difference 
between testing for interactions as against testing for associations 
while taking account of interactions. In her review, few studies 
have taken into consideration the gene–gene interactions. In our 
study, we include several studies which analyzed the gene–gene 
interactions. For example, De Luca et al. (119), studying a cohort 
of 231 patients suffering from schizophrenia, found a supposedly 
significant interaction between CRHBP rs1875999 and CRHR1 
rs16940665 as regards the seriousness of SB, and more recently, 
Perroud et al. (88), in their recent GENDEP clinical trial sample, 
reported NTRK2 and BDNF polymorphisms to interact signifi-
cantly in suicidal ideation.
Technological and Theoretical Limits
In our review, all of the studies of association are based on the 
hypothesis of the “common disease common variant” (CDCV). 
According to the CDCV hypothesis, common diseases are trig-
gered by common variants, with effects that range from small 
to modest. According to the alternative theory, the “common 
disease rare variant” (CDRV) hypothesis, there is an extremely 
high level of allelic heterogeneity for complex traits, with disease 
etiology being the collective result of numerous rare variants 
having moderate to high penetrances.
In terms of its practical implications, the issue may be split 
up into two parts. Should the CDCV hypothesis be valid, then 
the application of the paradigm of positional cloning to the 
task of mapping disease genes would be considerably facilitated 
since a common allele would be more easily located. If, on the 
other hand, common diseases are caused by rare variants, then 
the task of identifying such genetic susceptibility variants would 
represent a real challenge. Although there exist a substantial body 
of evidence to suggest that the CDCV and CDRV theories are 
both valid, a model for complex traits which would come closer 
to reality is likely to be that functional variants occur over a wide 
range of allele frequencies from rare to common, even for the 
same susceptibility gene (160). The technological progress made 
recently in high-throughput sequencing platforms should shortly 
enable the extension of association studies to rarely occurring 
and very uncommon variants, especially in targeted exon rese-
quencing. They predict that uncommon variants are likely to be 
enriched for functional alleles and to display larger effect sizes 
than do common variants, in accordance with the hypothesis 
that functional allelic variants are subjected to the pressure of 
purifying selection.
For identifying rare variants, exome sequencing in families is 
more effective than case–control studies. Given that disease alleles 
are shared among affected family members through identity-by-
descent, the number of alleles needing to be considered could be 
limited by segregation analysis. However, this method is more 
difficult with suicide, which is a rare event.
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To identify relevant disease-related genes, instead of inves-
tigating SNPs, another approach is to carry out genome-wide 
exploration to determine gains and losses of copy numbers. These 
copy number variants (CNVs) have no greater intrinsic patho-
genic potential than a single-nucleotide change, but their size 
means that they can potentially raise or reduce the gene product 
at each CNV intersecting a gene or to modify the genomic 
environment with cis or trans effects which are potentially 
far-reaching. Based on single-nucleotide polymorphism array 
data, Gross et  al. (161) followed the Penn-CNV standards to 
detect CNVs in 1608 cases (suicide and suicide attempt) and 
1133 controls. Although the initial algorithms determined the 
presence of CNVs on chromosomes 6 and 12 in seven and eight 
cases respectively, compared with none of the controls, visual 
inspection of the raw data did not support this finding. But the 
authors were unable to confirm these results by CNV-specific 
real-time polymerase chain reaction. Additionally, they did not 
find any association between the frequency or length of rare 
CNVs and SBs.
Using subjects who were collected as part of STAR*D, Perlis 
et  al. (162) genotyped 189 patients suffering from MD who 
had a history of attempted suicide, and 1073 subjects suffering 
from MDD but who had not previously attempted suicide. The 
implication of their results is that no distinction can be made 
between these two groups in terms of a given CNV, and that 
should a given CNV be associated with attempted suicide in MD, 
it would probably be a common one. In other words, they failed 
to identify any CNVs that were not reported in the Database 
of Genomic Variants, which suggests that suicide attempt status 
is not influenced by any copy changes in the STAR*D sample. 
According to the authors, to be able to observe any effect of a 
common CNV, it would be necessary to increase sample sizes 
>20- to 30-fold. Statistical limits are also an obstacle. For exam-
ple, there is a technological limit because the level of detection of 
the size of a CNV is also a limit. Despite technological advances 
for association studies, only a comparatively small part of the 
heritability of the majority of complex traits has received an 
explanation and the variants which the studies concerned have 
identified are characterized by small effect sizes. This circum-
stance has raised the major, controversial, question of where 
the “missing heritability” of complex disorders is hiding (163). 
According to Nadeau et al. (163), perhaps the role of heritability 
has been exaggerated. Another possibility is that the missing 
variants might be located in areas of the genome which have as 
yet been insufficiently explored or in classes of genetic variation 
which have as yet been insufficiently tested. Alternatively, perhaps 
the genetic variants are going undetected because of their rarity 
and the smallness of their effects. Or maybe the complexity of 
genetic mechanisms has been underestimated, in the sense that 
very numerous closely related genes may display effects which 
depend on context and are non-additive.
Further to that, Nadeau et  al. (163) raises the question of 
transgenerational genetic effects, whereby phenotype variations 
in the current generation may very likely result from genetic 
variants in preceding generations.
The more recent contribution made by epigenetic studies 
would appear to be an interesting path for understanding SBs. 
Epigenetic mechanisms, such as DNA methylation and chro-
matin restructuring, can be altered by environmental factors 
but the complexity of the epigenome is not fully understood 
(164). The recent review by Turecki et al. (165) assesses emerg-
ing data for the role of epigenetic mechanisms in stress-related 
psychiatric disorders. The Turecki team has published numer-
ous studies on epigenetic mechanisms that are possibly related 
to SBs. They have reported promoter-wide hypermethylation 
of the ribosomal RNA gene promoter (166), hypermethylation 
of the tropomyosin-related kinase B (167), hypermethyla-
tion in the promoter of the glucocorticoid receptor (168), or 
hypermethylation in the promoter of spermine oxidase (169), 
in the brain of suicide subjects. We may also cite the studies 
on BDNF promoter hypermethylation (170) or on SKA2 DNA 
methylation (171).
In conclusion, although the studies on the heritability of SB 
have shown a strong genetic component, genetic association 
studies have failed to clearly identify specific markers contribut-
ing to this genetic liability. Numerous genes appear to be involved 
in the emergence of SBs. Several neurobiological pathways are 
involved, with multiple interplay of genetic and environmental 
factors. While the complexity is daunting, advances in statistical 
and genetic methodologies as well as increasingly informative 
developmental studies can help sustain an approach of guarded 
optimism. A better understanding of the genes that are involved 
in SB and their interaction with genetic and non-genetic factors 
could help in the development of more effective screening, pre-
vention, and management of SB.
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